On July 16, Moderna fell 5.52% in regular trading, trading at $64.34/share, with turnover of $139 million. The decline was triggered by news of a substantial patent infringement settlement payment obligation.

Biopharmaceutical company Arbutus Biopharma announced it had received approximately $178 million as the first non-contingent payment share under a patent infringement settlement agreement with Moderna. Arbutus further stated it plans to return up to approximately $230 million in capital to shareholders starting in the third quarter. The sizeable payout raised investor concerns over Moderna's near-term profitability and cash flow outlook.

On the same day, Moderna announced the first patient had been dosed in a Phase 1 clinical trial of its investigational tumor-targeting cancer antigen therapy for solid tumors. However, this positive pipeline development failed to offset negative sentiment from the patent settlement. Notably, the broader Biotechnology sector traded higher, with AbbVie up 2.65%, Amgen up 2.84%, and Alnylam Pharmaceuticals up 1.77%, underscoring that Moderna's decline was company-specific rather than sector-wide.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)